Yahoo Poland Wyszukiwanie w Internecie

Search results

  1. 15 wrz 2022 · What management options are there in patients with persistent LV thrombus despite therapy?

    • View EPUB

      PK u!3Yoa«, mimetypeapplication/epub+zipPK u!3Y...

    • Linda S. Williams

      Many diseases with specific indications for specific...

    • PDF/Epub

      PK u!3Yoa«, mimetypeapplication/epub+zipPK u!3Y...

    • Trial

      Background—The Randomized Evaluation of Long-term...

  2. 23 wrz 2022 · On the basis of limited data, patients with nonischemic cardiomyopathy with LV thrombus should be treated with OAC for at least 36 months, with discontinuation if LV ejection fraction improves to >35% (assuming resolution of the LV thrombus) or if major bleeding occurs.

  3. Left ventricular (LV) thrombus is a feared complication of LV dysfunction associated with high rates of systemic embolism, morbidity, and mortality. Traditionally, LV thrombus has been associated with acute myocardial infarction (MI).

  4. Left ventricular (LV) thrombus is an increasingly recognised complication following anterior myocardial infarction and non-ischaemic cardiomyopathy. Whilst vitamin K antagonists (VKA) remain the only approved therapeutic option to reduce the risk of systemic thromboembolism including stroke, the off-label use of direct oral anticoagulants ...

  5. Management of LV thrombus (LVT) is challenging and crucial to prevent the potential development of thromboembolic complications such as stroke. Anticoagulation with warfarin is recommended for the prevention of thromboembolic events, but novel oral anticoagulants (NOAC) have been used in clinical practice without supporting evidence.

  6. Here we propose an algorithmic approach to the diagnosis and management of left ventricular (LV) thrombus following acute myocardial infarction (AMI) that begins with transthoracic echocardiography (TTE) with contrast within 24 hours of index myocardial infarction (MI).

  7. 14 wrz 2022 · We suggest that, on the basis of limited data, patients with NICM with LV thrombus should be treated with OAC for at least 36 mo, with dis-continuation if LVEF improves to >35% (assuming resolution of the LV thrombus) or if major bleeding occurs.

  1. Ludzie szukają również